



PATENT APPLICATION NO.: 10/575,236
ATTORNEY DOCKET: 58767.000013

IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number : 10/575,236 Confirmation No.: Unassigned
Applicant : Gougeon et al.
Filed : April 10, 2006
Title : USE OF SOMATOSTATIN OR ONE OF ITS ANALOGUES FOR
PREPARING A MEDICAMENT INTENDED TO REGULATE
THE OVARIAN FOLLICULAR RESERVE IN NON-
MENOPAUSAL WOMEN
TC/Art Unit : Unassigned
Examiner: : Unassigned
Docket No. : 58767.000013
Customer No. : 21967

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants submit attached Form PTO-SB/08A (modified) for consideration and request the references cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

The attached documents were cited by the European Patent Office in the International Search Report dated April 29, 2005 of the corresponding application and relevance as asserted by the Searching Authority is indicated on the enclosed copy of the Search Report.

Applicants respectfully point out that the submission of the listed references in this Information Disclosure Statement is not an admission that they are prior art or that they are material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made by Applicants.

For the convenience of the Examiner in considering the cited references, a copy of each of the cited references is enclosed with this communication. In considering the cited references, it may be noted by the Examiner that certain of the references may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited references. Any such markings were either present on the copies of the cited references obtained by the associated individuals, or were made thereon during the study of the references by the associated individuals.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated:

July 24, 2006

By:


Jeffrey T. Pérez

Registration No. 52,110

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)



Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/575,236
		Filing Date	April 10, 2006
		First Named Inventor	Chabrier de Lassauniere, et al.
		Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	1 of 1	Attorney Docket Number	58767.000013

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code Number-Kind Code (if known)					YES	NO
	1.	WO	02/072602	09-19-2002	Coy, et al.		<input type="checkbox"/>	<input type="checkbox"/>
	2.	WO	02/10192	02-07-2002	Albert, et al.		<input type="checkbox"/>	<input type="checkbox"/>
	3.	WO	01/96393 A2	12-20-2001	Davis, et al.		<input type="checkbox"/>	<input type="checkbox"/>
	4.	WO	97/01579	01-16-1997	Albert, et al.		<input type="checkbox"/>	<input type="checkbox"/>
							<input type="checkbox"/>	<input type="checkbox"/>

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
	5	NILSOSON ERIC, PH.D., DVM AND MICHAEL K. SKINNER, PH.D., Cellular interactions that control primordial follicle development and folliculogenesis, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; The Society of Gynecologic Investigation; pp. S17-S20, January 2001	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	6	MACLACHLAN ET AL., A Controlled Study of Luteinizing Hormone-Releasing Hormone Agonist (Buserelin) for the Induction of Folliculogenesis before In Vitro Fertilization, NEW ENGLAND JOURNAL OF MEDICINE; 320:19, 1233-7, 1989	<input type="checkbox"/>	<input type="checkbox"/>
	7	DE VET ET AL., Regulatie van vroege follikelontwikkeling, Tijdschriftvoor Fertilitetsonderzoek, Vol. 16, No. 1, pp. 2-9, 2000	<input type="checkbox"/>	<input checked="" type="checkbox"/>
	8	VAN DER MEER ET AL., , Octreotide, a somatostatin analogue, alters ovarian sensitivity to gonadotrophin stimulation as measured by the follicle stimulating hormone threshold in polycystic ovary syndrome, EUROPEAN SOCIETY FOR HUMAN REPRODUCTION AND EMBRYOLOGY; VOL. 13, NO. 6, pp. 1465-1469, 1998	<input type="checkbox"/>	<input type="checkbox"/>
	9	REUBI ET AL., A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors, EUROPEAN JOURNAL OF PHARMACOLOGY 456, pp. 45-49, 2002	<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.